THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
News Medical on MSN18h
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancerRegeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
Clinical Trials Arena on MSN10d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo aloneA treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...
Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...
(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company ... in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell lung cancer ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC) in Immuneering’s ongoing Phase 2a clinical trial of IMM-1-104 in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback